Clinical Trial Results:
The influence of exercise and hydration to the pharmacological response to inhaled terbutalin and salbutamol in men
Summary
|
|
EudraCT number |
2013-000483-29 |
Trial protocol |
DK |
Global end of trial date |
28 Aug 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Feb 2017
|
First version publication date |
09 Feb 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Wada_2012
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Bispebjerg University Hospital
|
||
Sponsor organisation address |
Bispebjerg Bakke 23, Copenhagen, Denmark, 2400
|
||
Public contact |
Respiratory Research Unit, Bispebjerg University Hospital, mhostrup@nexs.ku.dk
|
||
Scientific contact |
Respiratory Research Unit, Bispebjerg University Hospital, mhostrup@nexs.ku.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
17 Mar 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
28 Aug 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Aug 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate the pharmacokinetic effekt of the medicine under physical work and dehydration in healthy men
|
||
Protection of trial subjects |
Safety of the trial subjects was high prioritized. All procedures are well tolerated and at risk periods, the subjects were under surveillance so that a member of staff could intervene if needed. The study was performed under the GCP-guidelines.
|
||
Background therapy |
None | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 May 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 30
|
||
Worldwide total number of subjects |
30
|
||
EEA total number of subjects |
30
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
30
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Recruitment started on the 11th of September 2013 and ended on the 01st of july 2014. Recruitment took place in Denmark, mostly in the greater Copenhagen area. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Screening consisted of # Doctors examination # ECG and pulmonary function testing # incremental test | |||||||||||||||
Pre-assignment period milestones
|
||||||||||||||||
Number of subjects started |
30 | |||||||||||||||
Number of subjects completed |
30 | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Intervention (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Salbutamol | |||||||||||||||
Arm description |
Active substance: salbutamol | |||||||||||||||
Arm type |
Active comparator | |||||||||||||||
Investigational medicinal product name |
Ventoline
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Inhalation powder
|
|||||||||||||||
Routes of administration |
Inhalation use
|
|||||||||||||||
Dosage and administration details |
The subjects inhale 2x800 µg ventoline at either V1 or V2. At the other visit the subject recieves placebo.
At visit 3 and 4 the subjects inhale 2x800 µg ventoline.
|
|||||||||||||||
Arm title
|
Terbutaline | |||||||||||||||
Arm description |
- | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Terbutaline
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Inhalation powder
|
|||||||||||||||
Routes of administration |
Inhalation use
|
|||||||||||||||
Dosage and administration details |
8x 0.5 mg
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||
Reporting group title |
Salbutamol
|
||||||||||||||||||||||||||||||||
Reporting group description |
Active substance: salbutamol | ||||||||||||||||||||||||||||||||
Reporting group title |
Terbutaline
|
||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Salbutamol
|
||
Reporting group description |
Active substance: salbutamol | ||
Reporting group title |
Terbutaline
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Urine concentrations of terbutaline | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
During whole trial
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Repeated-measures analysis | ||||||||||||
Statistical analysis description |
Three factorial repeated-measures analysis of variance mixed linear model
|
||||||||||||
Comparison groups |
Salbutamol v Terbutaline
|
||||||||||||
Number of subjects included in analysis |
28
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
≤ 0.05 | ||||||||||||
Method |
ANOVA | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
1-sided
|
||||||||||||
lower limit |
- | ||||||||||||
upper limit |
- | ||||||||||||
Variability estimate |
Standard deviation
|
|
||||||||||||||||
Adverse events information [1]
|
||||||||||||||||
Timeframe for reporting adverse events |
During the whole trial
|
|||||||||||||||
Assessment type |
Systematic | |||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||
Dictionary name |
Nathional authority | |||||||||||||||
Dictionary version |
x
|
|||||||||||||||
Reporting groups
|
||||||||||||||||
Reporting group title |
Salbutamol
|
|||||||||||||||
Reporting group description |
Active substance: salbutamol | |||||||||||||||
Reporting group title |
Terbutaline
|
|||||||||||||||
Reporting group description |
- | |||||||||||||||
|
||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||
|
||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No non-serious adverse events were recorded |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/27167471 http://www.ncbi.nlm.nih.gov/pubmed/26044066 |